Cannabics Pharmaceuticals Financials
| CNBX Stock | USD 0.01 0 15.00% |
Cannabics |
Understanding current and past Cannabics Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cannabics Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Cannabics Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Cannabics Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cannabics Pharmaceuticals. Check Cannabics Pharmaceuticals' Beneish M Score to see the likelihood of Cannabics Pharmaceuticals' management manipulating its earnings.
Cannabics Pharmaceuticals Stock Summary
Cannabics Pharmaceuticals competes with Pmv Pharmaceuticals, MediciNova, Pharvaris, PepGen, and Anebulo Pharmaceuticals. CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US13764M1009 |
| Business Address | 3 Bethesda Metro |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cnbxpharma.com |
| Phone | 877 424 2429 |
| Currency | USD - US Dollar |
Cannabics Pharmaceuticals Key Financial Ratios
Cannabics Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Cannabics Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Cannabics Pharmaceuticals over time and compare it to other companies across industries.| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 | |||
| Beta | 1.52 | |||
| Z Score | -13.2 |
Cannabics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cannabics Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cannabics Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannabics Pharmaceuticals competition to find correlations between indicators driving Cannabics Pharmaceuticals's intrinsic value. More Info.Cannabics Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cannabics Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cannabics Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cannabics Pharmaceuticals Systematic Risk
Cannabics Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cannabics Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Cannabics Pharmaceuticals correlated with the market. If Beta is less than 0 Cannabics Pharmaceuticals generally moves in the opposite direction as compared to the market. If Cannabics Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cannabics Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cannabics Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Cannabics Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Cannabics Pharmaceuticals December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cannabics Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cannabics Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cannabics Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Cannabics Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cannabics Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | 0.0056 | |||
| Maximum Drawdown | 46.0 |
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.